Overview

Abaloparatide Before Total Knee Arthroplasty

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.

Phase:

Phase 4

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Radius Health, Inc.

Treatments:

Abaloparatide
Parathyroid Hormone-Related Protein